LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Harvard Bioscience Inc

Aperta

SettoreSettore sanitario

0.53 -7.02

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.53

Massimo

0.56

Metriche Chiave

By Trading Economics

Entrata

1.1M

-1.2M

Vendite

141K

21M

Margine di Profitto

-5.978

Dipendenti

330

EBITDA

1M

1.2M

Dividendi

By Dow Jones

Utili prossimi

12 mar 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.9M

24M

Apertura precedente

7.55

Chiusura precedente

0.53

Notizie sul Sentiment di mercato

By Acuity

17%

83%

23 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Harvard Bioscience Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 feb 2026, 23:47 UTC

Azioni calde

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 feb 2026, 22:59 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Grab Holdings to Buy U.S.-Based Stash Financial

11 feb 2026, 23:54 UTC

Utili

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 feb 2026, 23:50 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

11 feb 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 feb 2026, 23:49 UTC

Utili

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 feb 2026, 23:45 UTC

Utili

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 feb 2026, 23:42 UTC

Utili

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 feb 2026, 23:41 UTC

Utili

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 feb 2026, 23:40 UTC

Utili

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 feb 2026, 23:35 UTC

Discorsi di Mercato

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 feb 2026, 23:18 UTC

Discorsi di Mercato

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 feb 2026, 23:14 UTC

Discorsi di Mercato

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 feb 2026, 22:59 UTC

Utili

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 feb 2026, 22:59 UTC

Utili

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 feb 2026, 22:59 UTC

Utili

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 feb 2026, 22:58 UTC

Utili

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 feb 2026, 22:57 UTC

Utili

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 feb 2026, 22:54 UTC

Utili

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 feb 2026, 22:53 UTC

Utili

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 feb 2026, 22:47 UTC

Utili

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:47 UTC

Utili

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:23 UTC

Utili

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 feb 2026, 22:22 UTC

Utili

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 feb 2026, 22:22 UTC

Utili

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 feb 2026, 22:19 UTC

Utili

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 feb 2026, 22:18 UTC

Utili

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 feb 2026, 22:18 UTC

Utili

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 feb 2026, 22:18 UTC

Utili

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 feb 2026, 22:16 UTC

Utili

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Confronto tra pari

Modifica del prezzo

Harvard Bioscience Inc Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

0

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.3 / 0.3401Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

No Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

23 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat